Interestingly, our study revealed a seemingly paradoxical association regarding LMP2 expression: low pre-treatment LMP2 expression predicted a favorable major pathological response (MPR) to neoadjuvant chemoimmunotherapy (NACI) in NSCLC, whereas high LMP2 expression was associated with improved overall survival (OS). This evidence concerns the gene PSMB9 and non-small cell lung carcinoma.